| Day 3: Tuesday, September 25, 2012|
||Welcome: Partnership and Collaboration Announcements|
Centers for Medicare and Medicaid Innovation (CMMI) Challenge Update: News from the Front
Moderator: Edward Horton, MD, Joslin Diabetes Center
- Deliver better care at lower costs through continuous process improvement
- Identify, validate and scale innovative models to provide all beneficiaries with a seamless care experience
- Ensure patients receive the right care, at the right time, in the right setting—every time
Jim Hester, PhD, Centers for Medicare and Medicaid Innovation (CMMI)
|8:30 – 12:00
Clinical Technology Breakthroughs
Moderator: Sachin H. Jain, MD, MBA, Merck
||The Artificial Pancreas—A Holy Grail for Type 1 Diabetes? |
Henry Anhalt, DO, Animas Corporation
- Is this the next best thing to a diabetes cure?
- What are the risks of an artificial pancreas if not properly designed?
||Surgical “Cures” For Diabetes?|
Philip Schauer, MD, Cleveland Clinic
- Duodenal-jejunal bypass for type 2 diabetes sparks a metabolic change, causing blood sugar levels to drop and seeming to cure diabetes
- What are the clinical and financial implications of this “cure”?
David Cummings, MD, University of Washington
||Stopping Before You Start:|
New Technologies for Risk Identification and Screening
Robert E. Gerszten, MD, Massachusetts General Hospital
- How recent findings can improve diabetes risk prediction through metabolite levels
- Identify those at highest risk of developing diabetes with new technologies to start preventive measures early
David VanAvermaete, VeraLight
||Microchip-Based Implants for Managing Diabetes: |
How, Why and What about Safety and Security?
Robert Farra, MicroCHIPS
- Roll out microchip technology, benefits and considerations
- Evaluate clinician and patient data needs
- Discuss security challenges and possible approaches
Kevin Fu, PhD, UMASS; University of Michigan
||The Quantified Self on Steroids: |
Innovation in Devices, Pumps and Monitors
Howard Wolpert, MD, Joslin Diabetes Center
- How effective is technology for diabetes management?
- What is the future of technology in type 1 diabetes?
||Clinical Applications in Diabetes Population Health:|
The Good, the Bad and the Ugly
Moderator: Martin J. Abrahamson, MD, FACP, Joslin Diabetes Center
- Evaluate the impact of clinical diabetes applications on A1C and LDL testing rates and laboratory values
- Is participation in diabetes population health programs associated with appropriate clinical control of A1C and LDL values?
- Do members of all ages benefit from participation in diabetes population health programs?
- Discuss future applications for diabetes in population health management from a joint venture
Terry Golash, MD, Aetna
James L. Holly, MD, Southeastern Texas Medical Association (SETMA)
Brandon Savage, MD, Caradigm
||Challenge Grant Announcements and Private Funding Opportunities|
Wil Yu, US Department of Health and Human Services (HHS)
- Foster radical rethinking of diabetes control approaches and impact measures given the scale of the epidemic
- Diabetes Innovation Challenge: Create a contest shaped by “public crowdsourcing” for the best innovations to help people living with diabetes
- Challenge grants for patient engagement technologies
- Innovation in philanthropy: Supporting pioneering projects that bring fresh thinking and unconventional approaches to bear on the mostpressing health and health care problems
Patricia Doykos, Bristol-Myers Squibb Foundation
Angela Moskow, Sanofi US
Brian C. Quinn, PhD, Robert Wood Johnson Foundation
||Next Steps, Follow-up Plans and Adjourn|
John L. Brooks III, Joslin Diabetes Center